其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Lanolin Alcohols CAS Registry Number: 8027-33-6 羊毛脂醇

Additional Names: Wool alcohols
Trademarks: Amerchol 400 (Amerchol); Ceralan (Amerchol); Emery 1780 (Henkel); Eucerin (Beiersdorf); Fancol LA (Fanning); Hartolan (Croda); Ritawax (R.I.T.A.)
Literature References: Complex combination of organic alcohols obtained by the saponification of lanolin. Composed of monohydric and dihydric aliphatic alcohols and sterols, primarily cholesterol and lanosterol, q.q.v. Prepn: L. I. Conrad, K. Motiuk, J. Soc. Cosmet. Chem. 6, 344 (1955). Composition: M. L. Schlossman, J. P. McCarthy, Contact Dermatitis 5, 65 (1979). Clinical evaluation of moisturizing capacity: J. Sindhvananda et al., J. Soc. Cosmet. Chem. 44, 279 (1993).

Iron Dextran CAS Registry Number: 9004-66-4 右旋糖酐铁

Additional Names: Dextran iron complex
Trademarks: DexFerrum (American Regent); Imferon (Fisons); INFeD (Watson)
Literature References: Complex of ferric hydroxide with dextran, q.q.v. Prepn: E. London, G. D. Twigg, US 2820740 (1958 to Benger); US RE 24642 (1959); J. R. Herb, US 2885393 (1959 to Laros). Use in treatment of iron-deficiency anemia: I. M. Baird, D. A. Podmore, Lancet 264, 942 (1954). Acute toxicity: R. P. Beliles, Toxicol. Appl. Pharmacol. 23, 537 (1972). Comparison of different formulations: R. Lawrence, PDA J. Pharm. Sci. Technol. 52, 190 (1998). Mössbauer spectroscopy and x-ray diffraction study: B. Knight et al., J. Inorg. Biochem. 73, 227 (1999). Use as an iron supplement for anemic piglets: A. K. Egeli, T. Framstad, Res. Vet. Sci. 66, 179 (1999). Clinical evaluation in iron deficiency: J. C. Barton et al., Am. J. Med. 109, 27 (2000). Review of carcinogenicity studies: IARC Monographs 2, 161-178 (1973); of clinical experience: D. L. Burns et al., Nutrition 11, 163-168 (1995); of toxicity profile: D. L. Burns, J. J. Pomposelli, Kidney Int. 55, S119-S124 (1999).

D -Chalcose CAS Registry Number: 3150-28-5 4,6-二脱氧-3-O-甲基-alpha-D-木糖基-吡喃己糖

CAS Name: 4,6-Dideoxy-3-O-methyl-D-xylo-hexose
Additional Names: 4,6-dideoxy-3-O-methyl-D-glucose; lankavose
Percent Composition: C 51.84%, H 8.70%, O 39.46%
Literature References: Component of chalcomycin and lankamycin, q.q.v. Prepn from chalcomycin and structure: Woo et al., J. Am. Chem. Soc. 83, 3352 (1961). Stereochemistry: Woo et al., ibid. 84, 1066 (1962); Foster et al., J. Chem. Soc. 1965, 2318. Synthesis: Kochetkov, Usov, Tetrahedron Lett. 1963, 519; McNally, Overend, Chem. Ind. (London) 1964, 2021; Lawton et al., Can. J. Chem. 47, 2899 (1969). Synthesis of DL-form: R. M. Srivastava, R. K. Brown, Can. J. Chem. 48, 830 (1970); K.Torssell, M. P. Tyagi, Acta Chem. Scand. B 31, 1 (1977); S. Danishefsky, J. F. Kerwin, J. Org. Chem. 47, 1597 (1982).

Hydnocarpic Acid CAS Registry Number: 459-67-6

CAS Name: (1R)-2-Cyclopentene-1-undecanoic acid
Additional Names: 11-(2-cyclopenten-1-yl)undecanoic acid
Percent Composition: C 76.14%, H 11.18%, O 12.68%
Literature References: Component of chaulmoogra oil; naturally occurring in d-form. Isoln from seeds of Hydnocarpus wightiana Blume or H. anthelmintica Pierre, Flacourtiaceae, or from the seeds of Taraktogenos kurzii King, Bixaceae: F. B. Power, M. Barrowcliff, J. Chem. Soc. 87, 884 (1905); ibid. 91, 557 (1907). Structure: R. L. Shriner, R. Adams, J. Am. Chem. Soc. 47, 2727 (1925). Synthesis of dl-hydnocarpic acid: D. G. M. Diaper, J. C. Smith, Biochem. J. 42, 581 (1948). Toxicity data: Anderson, Int. J. Lepr. 2, 39 (1934). Antimicrobial spectrum: P. L. Jacobsen, L. Levy, Proc. West. Pharmacol. Soc. 15, 44 (1972). Mechanism of action: eidem, Antimicrob. Agents Chemother. 3, 373 (1973). Chromatographic determn in seed oils: W. W. Christie et al., Lipids 24, 116 (1989).

DL -Fructose CAS Registry Number: 6035-50-3

Additional Names: a-Acrose; methose
Percent Composition: C 40.00%, H 6.71%, O 53.28%
Literature References: Component of formose (polymerization product of formaldehyde): Vogel, Helv. Chim. Acta 11, 370 (1928).

Methyl Allyl Trisulfide CAS Registry Number: 34135-85-8 甲基烯丙基三硫醚

CAS Name: Methyl-2-propenyl trisulfide
Additional Names: allyl methyl trisulfide; methyl 2-propenyl trisulfane; MATS
Percent Composition: C 31.54%, H 5.29%, S 63.16%
Literature References: Component of garlic oil which inhibits platelet aggregation. Synthesis, identification by GC: D. M. Oaks et al., Anal. Chem. 36, 1560 (1964). Isoln from garlic oil, effect on platelet-rich plasma: T. Ariga et al., Lancet 1, 150 (1981). Improved synthesis: A. W. Mott, G. Barany, Synthesis 1984, 657. Use as antithrombotic agent: JP Kokai 82 209218 (1982 to Alcon), C.A. 98, 95692n (1983).

Diallyl Trisulfide CAS Registry Number: 2050-87-5 二烯丙基三硫醚

CAS Name: Di-2-propenyl trisulfide
Additional Names: allyl trisulfide
Trademarks: DATS
Percent Composition: C 40.41%, H 5.65%, S 53.94%
Literature References: Component of the essential oil of garlic; formed by pyrolysis of diallyl disulfide. Major component of the Chinese traditional medicine, allitridium. Exhibits antifungal, antitumor and antioxidant activity. Isoln from garlic oil: F. W. Semmler, Arch. Pharm. 230, 434 (1892); E. Block et al., J. Am. Chem. Soc. 110, 7813 (1988). Synthesis: B. Milligan et al., J. Chem. Soc. 1961, 4850; A. Banerji, G. P. Kalena, Tetrahedron Lett. 21, 3003 (1980). Inhibitory effect on mammary tumor cells in vitro: S. G. Sundaram, J. A. Milner, Cancer Lett. 74, 85 (1993). Mechanism of action study: X. Hu et al., Arch. Biochem. Biophys. 336, 199 (1996). Antifungal activity: J. Shen et al., Planta Med. 62, 415 (1996).

Lazurite CAS Registry Number: 1302-83-6 群青类 (CI 77007; CI 77013)

Additional Names: Lapis lazuli; lasurite
Literature References: Composition: (Na,Ca)4(AlSiO4)3(SO4,S,Cl), E. S. Dana, A System of Mineralogy (John Wiley, New York, 6th ed., 1901) pp 432-433; C. S. Hurlbut, Jr., Dana's Manual of Mineralogy (John Wiley, New York, 17th ed., 1959) p 503.

Cupric Arsenite CAS Registry Number: 10290-12-7 亚砷酸铜

CAS Name: Arsonic acid copper(2+) salt (1:1)
Additional Names: arsenious acid copper(2+) salt (1:1); Scheele's green
Literature References: Compound of variable composition. Usually considered to be CuHAsO3; mol wt 187.46. Also reported as Cu(AsO2)2: Bhadraver, Bull. Chem. Soc. Jpn. 35, 1770 (1962). Prepd by reaction of a cupric salt with an alkaline or ammoniacal arsenite: R. N. Kust in Kirk-Othmer Encyclopedia of Chemical Technology vol. 7 (Interscience, New York, 3rd ed., 1979) p 102. See also: Colour Index vol. 4 (3rd ed., 1971) p 4667.

Ferric Ammonium Citrate CAS Registry Number: 1185-57-5 柠檬酸铁铵

CAS Name: 2-Hydroxy-1,2,3-propanetricarboxylic acid ammonium iron (3+) salt
Additional Names: ammonium ferric citrate; iron(III) ammonium citrate
Trademarks: FerriSeltz (Otsuka)
Literature References: Compounds of NH3, iron, and citric acid of undetermined formula and structure. Prepn: H. J. Kruse, H. C. Mounce, US 2644828 (1953 to Mallinckrodt). ESR characterization of green and brown forms: R. A. Uphaus, M. I. Blake, Naturwissenschaften 68, 270 (1981). Decomposition study: G. A. M. Hussein, Powder Technol. 80, 265 (1994). Use in prevention of anemia in pigs: B. G. Harmon et al., J. Anim. Sci. 26, 1051 (1967). Bioavailability: N. P. Wong et al., Nutr. Rep. Int. 29, 135 (1984). Clinical evaluation in iron deficiency anemia: M. Taniguchi et al., J. Nutr. Sci. Vitaminol. 37, 161 (1991); of use as an MRI contrast agent: S. Hirohashi et al., Magn. Reson. Imaging 12, 837 (1994).